Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

<del id="wkqc0"></del>

<del id="wkqc0"><sup id="wkqc0"></sup></del>

<ul id="wkqc0"></ul>

You are here: Industry Insights > Market News > Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

NERVONIC ACID

百靈威J&K 降冰片烯 175425

百靈威J&K 降冰片烯 175425

百靈威J&K 三(3-羥基丙基)膦

百靈威J&K 三(3-羥基丙基)膦

百靈威J&K 三正辛基氧化膦 318216

百靈威J&K 三正辛基氧化膦 318216

百靈威J&K 三(2-羧乙基)膦鹽酸鹽 312334

百靈威J&K 三(2-羧乙基)膦鹽酸鹽 312334

百靈威J&K 4,5-雙二苯基膦-9,9-二甲基氧雜蒽 134853

百靈威J&K 4,5-雙二苯基膦-9,9-二甲基氧雜蒽 134853

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

www.nmpa.comJanuary 04, 2023

Tag: Ainuovirine , lamivudine

Favorites

Recently, the innovative drug Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (trade name:復邦德) of Jiangsu Aidea Pharmaceutical Co., Ltd. is approved by China NMPA. This product is a compound medicine composed of Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate, which is indicated for the treatment of adult HIV-1 infected patients.

The marketing of this drug provides new treatment options for adult HIV-1 infected patients.

Previous:Mobocertinib succinate capsules approved for marketing with conditions

Next:China, New Zealand to further enhance science cooperation

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing - PharmaSources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.

You may like
More>>

LAMIVUDINE

lamivudine salicylate

lamivudine salicylate

'Lamivudine

Lamivudine

Lamivudine Impurity 13

Lamivudine Impurity 13

Dolutegravir*Lamivudine *
Tenofovir Disoproxil Fumarate

Dolutegravir*Lamivudine * Tenofovir Disoproxil Fumarate

Dolutegravir+Lamivudine

Dolutegravir+Lamivudine

Lamivudine USP38

Lamivudine USP38

99% up by HPLC Lamivudine 134678-17-4

99% up by HPLC Lamivudine 134678-17-4

Zidovudine and Lamivudine Tablets (300mg+150mg)

Zidovudine and Lamivudine Tablets (300mg+150mg)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號-182 滬公網(wǎng)安備31010402010101號
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight January 2025

PharmaSources Customer Service

<fieldset id="yq2i8"><table id="yq2i8"></table></fieldset>

<del id="yq2i8"></del>

<fieldset id="yq2i8"><table id="yq2i8"></table></fieldset>

<del id="yq2i8"></del>

<fieldset id="yq2i8"><table id="yq2i8"></table></fieldset>